HN2012000585A - Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina - Google Patents

Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Info

Publication number
HN2012000585A
HN2012000585A HN2012000585A HN2012000585A HN2012000585A HN 2012000585 A HN2012000585 A HN 2012000585A HN 2012000585 A HN2012000585 A HN 2012000585A HN 2012000585 A HN2012000585 A HN 2012000585A HN 2012000585 A HN2012000585 A HN 2012000585A
Authority
HN
Honduras
Prior art keywords
ceftaroline
compositions
methods
bacterial infections
treat bacterial
Prior art date
Application number
HN2012000585A
Other languages
English (en)
Inventor
Dirk Thye
George Talbot
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43757152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2012000585(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HN2012000585A publication Critical patent/HN2012000585A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES QUE COMPRENDEN CEFTAROLINA O UN PROFARMACO DE ESTAS (P. EJ. CEFTAROLINA FOSAMILIO) Y METODOS PARA TRATAR INFECCIONES BACTERIANAS, TALES COMO INFECCIONES COMPLICADAS DE LA PIEL Y SUS ESTRUCTURAS (CSSSI), Y LA NEUMONIA BACTERIANA ADQUIRIDA EN LA COMUNIDAD (NBAC). ADMINISTRANDO CEFTAROLINA O UN PROFARMACO O UN PROFARRMACO DE ESTA (P.ej..CEFTAROLINA FOSAMILO).
HN2012000585A 2009-09-21 2012-03-20 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina HN2012000585A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14

Publications (1)

Publication Number Publication Date
HN2012000585A true HN2012000585A (es) 2015-06-15

Family

ID=43757152

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2012000585A HN2012000585A (es) 2009-09-21 2012-03-20 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Country Status (24)

Country Link
US (2) US20110071114A1 (es)
EP (1) EP2480236A4 (es)
KR (1) KR20120083344A (es)
CN (1) CN102781451A (es)
AU (1) AU2010295269B2 (es)
BR (1) BR112012006250B1 (es)
CA (1) CA2774772A1 (es)
CL (1) CL2012000694A1 (es)
CO (1) CO6531417A2 (es)
CR (1) CR20120137A (es)
CU (1) CU20120048A7 (es)
DO (1) DOP2012000077A (es)
EA (1) EA029149B1 (es)
EC (1) ECSP12011739A (es)
GT (1) GT201200082A (es)
HN (1) HN2012000585A (es)
IL (1) IL218349A0 (es)
MX (2) MX2012003201A (es)
NI (1) NI201200045A (es)
PE (2) PE20121819A1 (es)
PH (1) PH12012500528A1 (es)
SG (1) SG178936A1 (es)
WO (1) WO2011035305A1 (es)
ZA (1) ZA201202924B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RU2610091C2 (ru) 2011-06-17 2017-02-07 Астразенека Аб (2S,5R)-5-[(бензилокси)амино]пиперидин-2-карбоксамид
CN107621512B (zh) * 2017-11-02 2020-07-31 扬子江药业集团有限公司 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
DK1310502T3 (da) * 2000-08-10 2009-09-07 Takeda Pharmaceutical Phosphonocephem-forbindelse
US20030186339A1 (en) * 2001-05-17 2003-10-02 Mcgill University Individualization of therapy with antibiotic agents
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
JP2010540448A (ja) * 2007-09-21 2010-12-24 フォレスト・ラボラトリーズ・ホールディングス・リミテッド 非経口投与に適したセフェム誘導体を含む可溶製剤

Also Published As

Publication number Publication date
AU2010295269B2 (en) 2014-06-05
CN102781451A (zh) 2012-11-14
PE20171176A1 (es) 2017-08-22
CR20120137A (es) 2012-05-28
DOP2012000077A (es) 2012-05-31
EA201200501A1 (ru) 2012-10-30
CU20120048A7 (es) 2012-10-15
CL2012000694A1 (es) 2012-08-31
ZA201202924B (en) 2012-12-27
US9629861B2 (en) 2017-04-25
IL218349A0 (en) 2012-04-30
US20110071114A1 (en) 2011-03-24
MX2012003411A (es) 2012-04-30
CA2774772A1 (en) 2011-03-24
BR112012006250A2 (pt) 2016-05-31
EA029149B1 (ru) 2018-02-28
NI201200045A (es) 2012-11-02
BR112012006250B1 (pt) 2021-07-06
US20150258126A1 (en) 2015-09-17
EP2480236A4 (en) 2013-04-17
MX2012003201A (es) 2012-05-08
WO2011035305A1 (en) 2011-03-24
AU2010295269A1 (en) 2012-04-12
CO6531417A2 (es) 2012-09-28
EP2480236A1 (en) 2012-08-01
PE20121819A1 (es) 2013-02-01
KR20120083344A (ko) 2012-07-25
PH12012500528A1 (en) 2019-06-14
ECSP12011739A (es) 2012-05-30
SG178936A1 (en) 2012-04-27
GT201200082A (es) 2014-12-22

Similar Documents

Publication Publication Date Title
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
NI201400046A (es) AGENTES iARN, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR)
PA8819201A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
MX2015011448A (es) Compuestos y sus usos para modular la hemoglobina.
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
GT201200165A (es) Triazolopiridinas
MX2019003738A (es) Compuestos antivirales.
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
CR11731A (es) Composiciones y procedimientos para su preparación y uso
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
MX347165B (es) Composicion efervescente en forma solida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales.
IN2014DN11201A (es)
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
IN2012DN03404A (es)
ECSP11011486A (es) Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente
BR112012026542A2 (pt) abordagem seletiva de tecido
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
PA8797801A1 (es) Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor
HN2012000585A (es) Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina
MX2015005734A (es) Metodos de tratamiento de enfermedades hepaticas.
BR112013000930A2 (pt) formulações de 14-epi-análogos de vitamina d e cmc
WO2012138731A3 (en) Activated nucleoside analog conjugates and methods of use thereof